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Gaining Perspective*Fernando Alfonso, MD, PHD, Javier Cuesta, MDSEE PAGE 877C ompared with the use of bare-metal stents(BMS), the introduction of drug-elutingstents (DES) drastically reduced the occur-
rence of both clinical and angiographic in-stent reste-
nosis (ISR) (1,2). Recent reports also suggest that
new-generation DES could provide a safety edge by
reducing the risk of stent thrombosis. The widespread
use of DES enabled the expansion of coronary inter-
ventions to increasingly complex patients (1). Howev-
er, ISR still develops in patients treated with DES,
especially when these devices are used in challenging
clinical and anatomic scenarios (2). The underlying
substrate of DES-ISR appears to be particularly com-
plex (2). This problem has major clinical implications
as the results of reinterventions for DES-ISR are
poorer than those seen in BMS-ISR (2). Recent guide-
lines suggest that both DES and paclitaxel-eluting
balloons (PEB) are very effective and, therefore, may
be equally used (recommendation/evidence IA) in
patients presenting with ISR (3). Nevertheless, the
therapy of choice for patients presenting with DES-
ISR still remains unsettled. Therefore, additional
studies are warranted to unravel potential outcome
differences between these 2 therapeutic modalities
to inform clinical decisions (3). From a clinical
perspective, a critical appraisal of the long-term efﬁ-
cacy and safety of these competing therapies would
provide uniquely valuable information.*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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In this issue of JACC: Cardiovascular Interventions,
Kufner et al. (4) present the long-term results of the
ISAR-DESIRE 3 (Intracoronary Stenting and Angio-
graphic Results: Drug Eluting Stent In-Stent Reste-
nosis: 3 Treatment Approaches) clinical trial (5). In
this study, 402 patients (500 lesions) presenting
with limus-DES-ISR were randomly allocated to PEB
(n ¼ 137/172 lesions), paclitaxel-eluting stents (PES)
(n ¼ 131/168 lesions), or conventional balloon angio-
plasty (BA) alone (n ¼ 134/160 lesions). Regarding theprimary endpoint (percentage of diameter stenosis at
6- to 8-month angiographic follow-up), PEB were
noninferior to PES, whereas both pharmacoactive
arms were signiﬁcantly superior to BA. These angio-
graphic results translated into clear long-term clinical
beneﬁts mainly driven by signiﬁcant reduction in
target-lesion revascularization (TLR) compared with
the BA arm. The risk of TLR was similar with PEB
versus PES but signiﬁcantly lower with PEB versus BA
(hazard ratio [HR]: 0.51, 95% conﬁdence interval [CI]:
0.34 to 0.74). As compared with PES, the risk of death/
myocardial infarction (MI) also tended to be lower
with PEB, whereas the risk of death was signiﬁcantly
reduced with PEB (HR: 0.38, 95% CI: 0.17 to 0.87).
Conversely, the risk of death/MI was identical with
PEB and BA. The investigators suggest that the sus-
tained efﬁcacy of PEB, without any trade-off in safety,
supports the role of PEB as an attractive therapeutic
option for patients with DES-ISR.
Kufner et al. (4) should be commended for
this elegant study that compared 3 therapeutic
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886alternatives (including 2 pharmacoactive strategies
that used the same drug) in this challenging
anatomical scenario. This systematic long-term anal-
ysis provides robust clinical evidence further sup-
porting the maintained safety and efﬁcacy of PEB in
patients with DES-ISR. Due to the clinical relevance of
the current ﬁndings, discussing some methodological
aspects would be of major interest.
First, the generalizability of the ﬁndings appears
promising as exclusion criteria were very limited in
this trial (5). Second, the possibility of bias appears to
be extremely low although some imprecision cannot
be ruled out due to the sample size. Due to the study
design, treatment allocation was not concealed but
blinded outcome assessors were used. There is a
possibility, however, that the indication for reinter-
ventions at follow-up would have been inﬂuenced by
their perceived risk beneﬁt. Treating recurrent ISR
in patients with a double metal layer or in those
previously treated with PEB might be considered as
less attractive than treating ISR after BA failure (2).
However, the magnitude of the outcome differences
in favor of the 2 pharmacoactive arms dispels any
potential concern in this regard (4).
Third,as theseﬁndingsdonotcomefromtheprimary
analysis of the trial, they should be considered explor-
atory in nature. Results, however, were consistent
among several pre-speciﬁed clinical and angiographic
subsets of interest that showed wide conﬁdence
estimates but no interaction between PEB and PES.
Fourth, regarding efﬁcacy, TLR at 3 years occurred
in 33.3% of cases treatedwith PEB and in 24.2% of those
treated with PES. Although this numeric difference
was not statistically signiﬁcant, the trend (p ¼ 0.11) in
favor of PES may be a cause for concern. Whether this
represents a chance ﬁnding or rather a real signal of
reduced relative efﬁcacy remains to be determined.
“Late” TLR (after the ﬁrst year) was similar and low
(<15%) for PEB, PES, and BA. As expected, the
landmark analyses revealed a clear step-down in the
TLR-free survival curves at the time of scheduled
angiography with all therapies. Interestingly, at this
precise time interval, TLR rates were identical for
PEB and PES, but then they slightly diverged in favor
of PES up to the ﬁrst year and subsequently run
parallel. Further studies with longer clinical follow-up
are required to conﬁrm and assess the implications—if
any—of these subtle efﬁcacy signals.
Fifth, the safety differences in favor of PEB are also
of major interest. After the ﬁrst year, curves tended
to diverge with rates of death/MI being 2-fold with PES
compared with PEB (12.3% vs. 6.3%, p ¼ 0.12). More-
over, unexpectedly, PEB showed a signiﬁcantly lower
risk of death at 3 years than did PES. Likewise,target-lesion thrombosis rates were numerically lower
with PEB than with PES (0.8% vs 1.6%) (4). The in-
vestigators clearly acknowledged that these safety
differences between PEB and PESmay well represent a
chance ﬁnding due to the post-hoc nature of the
analysis and the limited sample size. However, similar
ﬁndings on mortality have been recently reported in
the 2-year follow-up of the PEPCAD-China-ISR (Pro-
spective, Multicenter, Randomized Trial of Paclitaxel-
Coated Balloon versus Paclitaxel-Eluting Stent for the
Treatment of DES In-Stent Restenosis) trial (6) that
compared PEB with PES in patients with DES-ISR.
Similarly, data on compliance or actual duration of
the prescribed dual antiplatelet therapy (the protocol
just recommended to maintain it for 6 months) would
have been of major interest, but were not available.
One might speculate that it is likely that patients
treated with PES would have receivedmore frequently
this therapy for up to 1 year and, if this was the case,
the safety edge in favor of PEB would be reinforced.
Notably, the potential value of long-term dual anti-
platelet therapy in patients with ISR treated with DES
was suggested in a subanalysis of the PRODIGY trial
(Prolonging Dual Antiplatelet Treatment After Grading
Stent-Induced Intimal Hyperplasia) (7). In that study,
the use of 24-month dual antiplatelet therapy proved
to be safer (reducing the rate of death/MI) compared
with a shorter duration (6 months), without any
difference in bleeding (7).
A close scrutiny of the study results as dis-
cussed above may help to disclose some hypothesis-
generating ﬁndings but may also be misleading. In
this regard, the cautious and balanced interpretations
reached by Kufner et al. (4) certainly remain the best
scientiﬁc approach. Notwithstanding that the trial
was unpowered to detect safety differences, death
in particular, these long-term results are rather pro-
vocative and should pave the way for future studies.
Finally, we should keep in mind that in ISAR-
DESIRE-3 the comparator stent was an early genera-
tionDES. Recent studies consistently demonstrate that
in “de novo” lesions results of novel-generation DES
are clearly superior to those of early generation DES.
PREVIOUS STUDIES ON
LONG-TERM RESULTS OF PEB
Scheller et al. (8) reported the very long-term out-
comes of the pivotal study comparing PEB and BA in
patientswith BMS-ISR. In that study, PEBmaintained a
superior clinical efﬁcacy out to 5 years of follow-up.
Interestingly, although dual antiplatelet therapy was
maintained only for 4 weeks, no single case of stent
thrombosis was detected. Moreover, no signal of a late
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887“catch-up” phenomenon was seen and “late” TLR
(from 2 to 5 years) was only 3.7% and 5.6%, in the
BA and PEB arms, respectively. More recently, the
3-year results of the PEPCAD-DES (Treatment of
DES-In-Stent Restenosis With SeQuent Please Pacli-
taxel Eluting PTCA Catheter) randomized trial (9)
comparing PEB with BA in patients with DES-ISR
have been reported. Again, the superior efﬁcacy of
PEB was conﬁrmed with no signs of a late “catch-up”
phenomenon on TLR at follow-up (9). The current
analysis by Kufner et al. (4) constitutes the ﬁrst report
on the long-term outcomes of PEB compared with DES
in patients with DES-ISR. All together, these studies
provide robust evidence supporting the maintained
efﬁcacy and safety of PEB in these patients.
PATHOPHYSIOLOGY OF ACUTE AND
LATE HEALING AFTER PEB
The mechanisms of lumen enlargement after BA and
repeat stent implantation in patients with ISR are well
established (2). With both strategies, tackling any re-
sidual stent underexpansion with high-pressure non-
compliant balloon dilations remains of paramount
importance (2). Recent studies using combined imag-
ing modalities suggest that in patients with DES-ISR,
BA enlarges the lumen by a combination of tissue ex-
trusion and additional stent expansion (10). However,
multiple intrastent residual neointimal dissections are
systematically detected in spite of excellent angio-
graphic results. In this scenario, repeat DES implan-
tation further increases the lumen by additional tissue
extrusion and stent expansion and virtually eliminates
the presence of intrastent dissections, providing not
only a larger but also a smoother lumen (10).
The analysis of healing patterns after PEB has also
generated major interest. Preliminary reports sug-
gested that PEB could induce a favorable healing
response with “neointimal remodeling,” progressive
reduction in tissue volume and disappearance of re-
sidual dissections (11). Agostoni et al. (12) performed
detailed combined morphometric and physiologic
analyses in 25 patients with ISR treated with PEB. At 6-
month follow-up, they found a decrease in neointimal
volume associated with an increase in lumen volume
compared with post-intervention results. Finally, the
SEDUCE (Safety and Efﬁcacy of a Drug Eluting Balloon
in Coronary Artery Restenosis) randomized trial (13)
compared healing characteristics of PEB versus ever-
olimus DES in patients with BMS-ISR. At 9-month
follow-up, the percentage of uncovered struts on op-
tical coherence tomography (primary endpoint) was
signiﬁcantly reduced with PEB versus DES, neointimal
hyperplasia tended to be larger after PEB, whereas thepercentage of malapposed struts was very low and
similar in both groups. This controlled mechanistic
study suggested that PEB was associated with better
healing characteristics although it tended to be less
effective than new generation DES (13).
Finally, it has been suggested that “preparing” the
underlying tissue before PEB therapy could enhance
the local effects of the drug. In this regard, the ISAR-
DESIRE-4 (Intracoronary Stenting and Angiographic
Results: Optimizing Treatment of Drug Eluting Stent
In-Stent Restenosis 4) trial will determine the po-
tential value of cutting balloon angioplasty before
PEB therapy.
FINAL REMARKS
ISR remains a signiﬁcant clinical problem (2). Patients
with ISR represent a high-risk cohort with increased
risk of adverse events in comparison with patients
who remain restenosis free. Recent data suggest
that the occurrence of angiographic ISR has prog-
nostic value even in asymptomatic patients (14). A
large study, also from the Munich group, (including
w10,000 patients with w15,000 treated lesions) sug-
gested that the presence of ISR during late angio-
graphic surveillance was an independent predictor
of 4-year mortality after adjusting for classical clinical
and angiographic factors (14).
Treatment of DES-ISR remains particularly chal-
lenging (2). In these patients, PEB certainly provide
encouraging results. The current study by Kufner et al.
(4) conﬁrms the safety and durable antirestenotic ef-
ﬁcacy of this therapeutic modality in patients with
DES-ISR with results comparable to those seen with
ﬁrst-generation DES. Very recently, however, the re-
sults of RIBS-V (Restenosis Intra-Stent of Bare Metal
Stents: Paclitaxel-Eluting Balloon vs. Everolimus-
Eluting Stent) (in patients with BMS-ISR) (15) and
RIBS IV (Restenosis Intra-Stent of Drug-Eluting Stents:
Paclitaxel-Eluting Balloon vs. Everolimus-Eluting
Stent) (in patients with DES-ISR) (16) randomized trials
demonstrated that everolimus-DES offer a superior
angiographic efﬁcacy compared with that of PEB.
Moreover, in patients with DES-ISR, a superior clinical
efﬁcacy of everolimus-DES was also demonstrated
(16). The currently ongoing analyses of the long-term
results of these 2 studies will help to gain perspective
on the role of PEB in the era of new-generation DES.
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